• cord blood platelet-rich plasma
• platelet-rich plasma
• wound healing

• Antibiotics
• Case report
• Growth factors
• Platelet-rich plasma
• Wound Infection
• Wound healing

• Adhesive capsulitis
• Frozen shoulder
• Meta-analysis
• PRP
• Periarthritis of shoulder
• Platelet-rich plasma
• Randomized Controlled Trials

• Humans
• Platelet-Rich Plasma
• Bursitis/therapy
• Randomized Controlled Trials as Topic/methods
• Treatment Outcome
• Range of Motion, Articular
• Quality of Life
• Shoulder Joint/physiopathology
• Shoulder Pain/therapy
• Pain Measurement

• 2021MS454 Sichuan Provincial Administration of Traditional Chinese Medicine
• 22-B07 The special fund for 100 Talents Program of the Affiliated Hospital of Chengdu University of TCM
• 030058047 The scientific research promotion plan of "Xinglin Scholars" Discipline Talents of Chengdu University of Traditional Chinese Medicine

• hTERT gene
• Mesenchymal stem cell
• Microparticle
• Platelet

• Telomerase/genetics
• Telomerase/metabolism
• Humans
• Mesenchymal Stem Cells/metabolism
• Mesenchymal Stem Cells/cytology
• Coculture Techniques
• Umbilical Cord/cytology
• Umbilical Cord/metabolism
• Blood Platelets/metabolism
• Cell-Derived Microparticles/metabolism
• Integrin beta3/genetics
• Integrin beta3/metabolism
• Platelet Membrane Glycoprotein IIb/metabolism
• Platelet Membrane Glycoprotein IIb/genetics
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism

• fibrin(ogen)
• matrix
• platelet-rich plasma
• protein-rich platelet concentrate
• tissue regeneration
• tissue repair
• ultrafiltration

• Humans
• Platelet-Rich Plasma/metabolism
• Platelet-Rich Plasma/chemistry
• Wound Healing
• Regeneration
• Animals
• Blood Platelets/metabolism
• Intercellular Signaling Peptides and Proteins/metabolism

• aesthetic medicine
• growth factors
• platelet-rich fibrin
• platelet-rich plasma
• tissue regeneration

• Humans
• Platelet-Rich Plasma/metabolism
• Platelet-Rich Plasma/chemistry
• Regenerative Medicine/methods
• Platelet-Rich Fibrin/metabolism
• Wound Healing
• Blood Platelets/metabolism
• Animals
• Regeneration
• Cell Proliferation

• Si-DLC implant
• blood-derived products
• macrophages
• ovine model

• anticoagulants
• growth factors
• platelet-rich plasma
• regenerative medicine

• PRP
• Platelet-Rich plasma
• cartilage
• charges
• injection
• musculoskeletal injury
• tendinitis

• Humans
• Female
• Male
• Injections
• Knee Joint
• Elbow
• Platelet-Rich Plasma
• Demography
• Injections, Intra-Articular
• Treatment Outcome
• Osteoarthritis, Knee

• PRP
• exosomes
• extracellular vesicles
• platelet-rich plasma
• regenerative medicine

• Blood Platelets
• Cell Communication
• Extracellular Vesicles
• Platelet-Rich Plasma
• Regenerative Medicine

• KK-2022/00038 This study was funded by the Basque Country Government (Spain) under the research and development project Elkartek (reference KK-2022/00038).

• ear drum perforation
• platelet rich fibrin
• tympanoplasty

• 35168/17.12.2021 Iuliu Hațieganu University of Medicine and Pharmacy

• dendrimers
• drug delivery
• gold nanoparticles
• nano-biotechnology
• silver nanoparticles
• tumour

• Humans
• Tissue Distribution
• Neoplasms/pathology
• Drug Delivery Systems
• Antineoplastic Agents/therapeutic use
• Nanoparticles/chemistry
• Nanotechnology

• Fundación CajaCanarias

• PRP
• classification
• medical device
• platelet-rich plasma
• regenerative medicine
• tissue engineering

The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and centrifuged, and the collected PRGF was activated and distributed into two groups: (i) mPRGF: a PRGF membrane maintained at 37 °C for 30 min; (ii) IS5+30: mPRGF incubated at 37 °C for 5 min and then incubated at 56 °C for 30 min. The content of both membranes was analyzed for several growth factors such as IgE and the complement activation, as well as biological activity on different ocular surface cells. Furthermore, the physical and mechanical characterizations were also evaluated. IS5+30 completely reduced the complement activity and decreased the IgE while preserving the concentration of the main growth factors. IS5+30 induced similar biological activity regarding mPRGF on the different ocular surface cells analyzed. Furthermore, no significant differences in release kinetics or fibrin degradation were observed between both membranes. Summarizing, IS5+30 totally reduces complement activity while preserving the concentration of most growth factors and their biological activity. Furthermore, the physical and mechanical properties of the fibrin membrane are preserved after heat inactivation.

There is scarce information about bovine platelet-rich plasma/platelet-rich gel (PRP/PRG) and related hemocomponents (HCs), such as platelet lysates (PLs), including growth factor (GF) and cytokine concentrations, and how the stability of these biomolecules could be affected by time and temperature. This study aimed to evaluate the release and stability of transforming growth factor beta 1 (TGF-β₁), interleukin 4 (IL-4), and tumor necrosis factor alpha (TNF-α) contained in bovine pure PRP (P-PRP) and temperature-induced PL (TIPL) coming from a similar platelet concentrate (PC) at 4 and 37°C at 3 and 96 h. Platelet concentrates (PCs) presented a 1.7-fold concentration of platelets (PLTs) with negligible counts of white blood cells (WBCs) when compared to the counts for these cells in whole blood. TGF-β₁ concentrations were significantly lowest in plasma followed by TIPL, chemical-induced PL (CIPL), and P-PRP. IL-4 and TNF-α concentrations did not differ between HCs. TGF-β₁ concentrations were negatively affected in P-PRPs stored at 4°C at 3 and 96 h, whereas those from P-PRP maintained at 37°C presented similar concentrations to TIPL stored at both temperatures over time. IL-4 and TNF-α concentrations were not affected by time or temperature in any of the HCs evaluated. Pure PRGs released additional quantities of GF and cytokines over time when compared with HCs stored over 96 h at 4 and 37°C. The method, either chemical or physical, used for platelet activation or damage produces a different GF and cytokine release pattern, which makes to each evaluated HCs different despite they come from a similar bovine PC. P-PRP activated with calcium gluconate and maintained at 37°C, which polymerizes in P-PRG, showed the best GF and cytokine release/denature profile compared with the rest of the HCs evaluated.

Wound dressing design is a dynamic and rapidly growing field of the medical wound-care market worldwide. Advances in technology have resulted in the development of a wide range of wound dressings that treat different types of wounds by targeting the four phases of healing. The ideal wound dressing should perform rapid healing; preserve the body’s water content; be oxygen permeable, non-adherent on the wound and hypoallergenic; and provide a barrier against external contaminants—at a reasonable cost and with minimal inconvenience to the patient. Therefore, choosing the best dressing should be based on what the wound needs and what the dressing does to achieve complete regeneration and restoration of the skin’s structure and function. Biopolymers, such as alginate (ALG), chitosan (Cs), collagen (Col), hyaluronic acid (HA) and silk fibroin (SF), are extensively used in wound management due to their biocompatibility, biodegradability and similarity to macromolecules recognized by the human body. However, most of the formulations based on biopolymers still show various issues; thus, strategies to combine them with molecular biology approaches represent the future of wound healing. Therefore, this article provides an overview of biopolymers’ roles in wound physiology as a perspective on the development of a new generation of enhanced, naturally inspired, smart wound dressings based on blood products, stem cells and growth factors.

• biopolymers
• growth factors
• phases of healing
• platelet-rich plasma (PRP)
• stem cells
• wound dressing

• Alginates/chemistry
• Alginates/therapeutic use
• Bandages
• Biopolymers/therapeutic use
• Chitosan/therapeutic use
• Humans
• Wound Healing/physiology

There are 422 million diabetic people in the world. 25% of these individuals are diagnosed with diabetic foot ulcer (DFU). 20% of patients with DFU will suffer amputation of the lower limbs. Following amputation procedures, the mortality rate of patients is over 70% in 5 years. Diabetes has no cure and, therefore, treatment aims to prevent and treat its complications. Autologous platelet-rich plasma (PRP) has been shown to be a therapeutic tool for many types of disorders, including the treatment of DFU. This manuscript aims to carry out a review to provide more knowledge about the efficacy and safety of autologous PRP for wound closure in patients with DFU. The majority of studies included in this review state that PRP promotes improvement of DFU lesions by accelerating tissue healing processes. However, many studies have a small sample size and thus require larger sample range in order to improve robustness of data in the literature.

• Diabetic foot ulcer
• Platelet-rich plasma
• Wound healing
• Tissue regeneration
• Inflammation

Intra-articular infiltration of platelet-rich plasma (PRP) is an alternative therapeutic option to classic hyaluronic acid for the treatment of symptomatic knee osteoarthritis (KOA). However, variation in preparation methods and quality assessment of PRP makes the study of its real clinical efficacy difficult.

To (1) evaluate the clinical efficacy of a characterized PRP product prepared in a standardized manner and in a closed-system for the treatment of KOA and to (2) evaluate the association of the clinical response to PRP-related variables.

Case series; Level of evidence, 4.

We recruited 130 patients with nonoperative KOA and evaluated them for 1 year. PRP was prepared from a donation of autologous blood, obtaining 3 aliquots of approximately 10mL of product, which were frozen, allowing platelet disruption, platelet factor release, and long-term storage, until administration. Patients were treated 3 consecutive times every 4 weeks with an intra-articular PRP knee injection under sterile conditions. Complete blood count was performed on the whole-blood sample and the processed PRP before freezing it, for product quality assessment. Patients were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and basic satisfaction scale at 3 months, 6 months, and 1 year after intervention.

Quality assessment confirmed a leukocyte-poor PRP product (white blood cell count, 0.09 ± 0.09 × 10⁹/L) with a high platelet purity (platelet count, 630.86 ± 191.75 × 10⁹/L). WOMAC scores improved, and basic satisfaction was achieved in 70% of patients. No adverse events were reported. No correlations were observed between PRP quality parameters and clinical results. PRP complete treatment production costs were €108/US$125 (€36/US$41.6 per injection).

This standardized PRP production method resulted in improved WOMAC scores at 1 year postoperatively in 70% of patients with KOA. This technique was safe and affordable and ensured consecutive infiltrations with the same product to each patient.

Mastoidectomy is a surgical procedure for the treatment of chronic otitis media. This study investigated the ability of rat stromal vascular fraction cells (rSVF) in combination with polycaprolactone (PCL) scaffolds and osteogenic differentiation-enhancing blood products to promote the regeneration of mastoid bone defect. Twenty male Sprague Dawley rats were randomly divided according to obliteration materials: (1) control, (2) PCL scaffold only, (3) rSVFs + PCL, (4) rSVFs + PCL + platelet-rich plasma, and (5) rSVFs + PCL + whole plasma (WP). At 7 months after transplantation, the rSVFs + PCL + WP group showed remarkable new bone formation in the mastoid. These results indicate that SVFs, PCL scaffolds, and blood products accelerate bone regeneration for mastoid reconstruction. Autologous SVF cells with PCL scaffolds and autologous blood products are promising composites for mastoid reconstruction which can be easily harvested after mastoidectomy. With this approach, the reconstruction of mastoid bone defects can be performed right after mastoidectomy as a one-step procedure which can offer efficiency in the clinical field.

• autologous growth factor
• mastoidectomy
• osteogenesis
• polycaprolactone (PCL) scaffold
• stromal vascular fraction cells

In the 1990s, the role of platelets in inflammation and tissue healing was finally recognized. Since then, the clinical use of platelet-derived products (hemocomponents), such as, platelet-rich plasma (PRP), markedly increased. The promise of a more economical option of a disease-modifying treatment led to the intensive and continuous research of PRP products and to its widespread clinical use. A number of protocols and commercial kits have been developed with the intention of creating a more practical and reliable option for clinical use in equine patients. Still, the direct comparison between studies is particularly challenging due to the lack of standardization on the preparation methods and product composition. The incomplete reports on PRP cellular concentration and the poorly designed in vivo studies are additional matters that contest the clinical efficiency of this biomaterial. To overcome such challenges, several in vitro and in vivo studies have been proposed. Specifically, experiments have greatly focused in protocol optimization and its effect in different tissues. Additionally, in vivo studies have proposed different biological products envisioning the upgrade of the anti-inflammatory cytokines trusting to increase its anti-inflammatory effect. The individual variability and health status of the animal, type of tissue and condition treated, and protocol implemented are known to influence on the product's cell and cytokine composition. Such variability is a main clinical concern once it can potentially influence on PRP's therapeutic effects. Thus, lack of qualitative and quantitative evidence-based data supporting PRP's clinical use persists, despite of the numerous studies intended to accomplish this purpose. This narrative review aims to critically evaluate the main research published in the past decade and how it can potentially impact the clinical use of PRP.

• equine
• musculoskeletal disease
• orthopedics
• platelet-rich plasma
• sports medicine

• Platelet-rich plasma
• hyaluronic acid
• preparation
• protocol
• rat

• Platelet derivatives
• platelet lysates
• platelet rich fibrin
• platelet-rich plasma
• quality control
• standardization

• Biomaterial
• bone regeneration
• platelet
• platelet-rich fibrin
• tissue engineering

• cell reprogramming
• cell source
• in vitro platelet production
• megakaryocyte differentiation
• platelet transfusion

• Blood Platelets
• Cell Differentiation
• Humans
• Megakaryocytes
• Platelet Transfusion
• Thrombopoiesis

• Military drill injury
• Plantar fasciitis
• Platelet- rich plasma (PRP)
• Rehabilitation
• Stress fracture

Platelet rich plasma (PRP) is widely used in orthopaedics, but is still heavily debated. Therefore, a survey among the German “Working Group for Clinical Tissue Regeneration” of the German Society of Orthopaedics and Traumatology was conducted to achieve a consensus about the current therapeutical potential of PRP.

A first survey (n = 65 experts, all orthopaedic/trauma surgeons) was conducted (n = 13 questions). Following, a second round (n = 40 experts) was conducted with 31 questions to achieve consensus in 5 categories: three most common indications, PRP application, future research areas.

Therapeutic PRP application was regarded as useful (89%), possibly even more important in the future (90%). Most common indications were tendon pathologies (77%), osteoarthritis (OA) (68%), muscle injuries (57%) and cartilage damage (51%). Consensus was reached in 16/31 statements. The application of PRP for early knee OA (Kellgren-Lawrence grade II) was regarded as potentially useful, as well as for acute and chronic tendinopathies. For chronic lesions (cartilage, tendons), multiple injections (2–4) were seen preferable to singular injections. However, no sufficient data exists on the time interval between the injections. Standardization of PRP preparation, application, frequency, as well as determining the range of indication is strongly recommended.

There is a need of further standardization of the PRP preparation methods, indication and application protocols for knee OA and other indications, which must be further evaluated in basic science studies and randomized controlled clinical trials.

Consensus of expert opinion, Level V.

• Cartilage
• Consensus statement
• Muscle injuries
• Osteoarthritis
• Platelet-rich-plasma (PRP)
• Tendon pathologies